Accelerating Medical Device Projects,
Reaching Development Milestones.
Solutions spanning the entire Medical Device development pathway from project initiation to commercial supply.
Expert in Medical Device Biocompatibility, specialising in the application of the ISO 10993 series of standards to evaluate novel Medical Devices.
Supporting Medical Device Development Projects throughout their project lifecycle
Medical Device Solutions
-
Kickstart your Medical Device project by:
Defining clear Product Requirements
Defining User Requirements
Developing a robust Design Plan
Assessing the competitive landscape
Assessing project feasibility
-
Initial and ongoing Risk Assessment activities, in compliance with ISO 14971.
Biological Risk Assessments
Review and critically assess all available data
Construct a detailed Biological Evaluation Plan.
-
Develop a preclinical strategy to verify Device performance.
Identify critical endpoints, develop robust assays and focus your data.
Build confidence in performance and shorten the time to market with a robust and focused preclinical dataset.
Generate powerful preclinical proof of concept data to aid your fund-raising activities and for publication.
-
Medical Device Manufacturing:
Contract Manufacturing Organisation selection
Raw materials risk assessment and biological evaluation
Sterilisation methods and validation process
Device Release Tests and Specifications
Manufacturing risk assessments such as Failure Mode Effects Analysis (FMEA)
Technical transfer of processes and know-how
-
For Medical Devices requiring terminal Sterilisation:
The selection of sterilisation methods
ISO 11737; Microbiological Methods
ISO 11137; Sterilisation of healthcare products - Radiation
Bacterial Endotoxin testing; LAL methods (Ph. Eur. 2.6.14)
Monocyte Activation Test (Ph. Eur. 2.6.30)
-
ISO 10993 compliant biocompatibility packages:
Identify the right CRO’s
Define your study plans
Monitoring ongoing studies
Collate and interpret reports
Individual studies or entire Biological Evaluation plans.
Experienced in a range of in vitro and in vivo testing strategies :
Genotoxicity (ISO 10993-3; In vivo comet test and Bacterial Ames test)
Hemocompatibility (ISO 10993-4; interactions with human blood)
Cytotoxicity (ISO 10993-5; L929 Cells – Extract Method)
Sensitisation (ISO 10993-10; Guinea Pig Maximisation test)
Intracutaneous Reactivity (ISO 10993-10; Intradermal reactivity in the rabbit)
Systemic Toxicity (ISO 10993-11; Systemic Toxicity)
Pyrogenicity (USP41; Pyrogen test in the Rabbit)
Endotoxin testing: Monocyte Activation Test (Pharm. Eur. 2.6.30) & Bacterial Endotoxin testing; LAL methods (Ph. Eur. 2.6.14)
Chemical Characterisation (ISO 10993-18; Leachables and Extractables)
Toxicological Risk Assessment (ISO 10993-17: Toxicological risk assessment of medical device constituents
Sterilisation validation (ISO 11737; Methods and ISO 11137; Sterilisation)
Committed to ensuring that proper provision has been made for the welfare of animals used in animal tests to assess the biocompatibility of materials used in medical devices (ISO 10993-2).
-
Device supply for clinical trial or commercial sale.
Risk assessing manufacturing non-compliances
Supplier change control risk assessment
Investigation of Out of Specification test results